BAY-707
| Target | NUDT1 |
| Targeted domain | Active site |
| Mode of action | Inhibitor |
| Control | BAY-604 |
| Recommended cellular usage concentration | 0.001 - 1 µM |
| In vivo use | yes |
| Donated by | Bayer |
Probe criteria
| Inhibitor/agonist potency: goal is < 100 nM (IC50, KD>/sub>) | Surpasses criterion: IC50 2.3 nM |
| Selectivity within target family: > 30-fold | BAY-707 is a selective NUDT1 (MTH1) inhibitor across the Nudix family when tested in Tm shift assay |
| Selectivity outside target family | Clean in-house kinase panel (30 kinases); Clean PDSP scan with the closest hit on GABAA/BZP (pKi = 5.8) |
| On target cell activity for cell-based targets: goal is < 1 µM IC50/EC50 | Surpasses criterion: cellular target engagement: EC50 7.6 nM (CETSA) |
| Control compound (100 times less potent than the probe) | Surpasses criterion: IC50 >20000 nMTwo hits in PDSP scan: GABAA/BZP (Ki = 224.22 nM) and DRD4 (Ki = 735.98 nM) |